Related Experiment Videos
Liposomes and ISCOMs.
Gideon F A Kersten1, Daan J A Crommelin
1Laboratory for Product and Process Development, National Institute of Public Health and the Environment, PO Box 1, 3720 BA, Bilthoven, The Netherlands. gideon.kersten@rivm.nl
Vaccine
|January 28, 2003
Summary
Liposomes and ISCOMs are versatile antigen delivery vehicles. Recent advancements focus on optimized design and defined saponins, with clinical trials and registered liposomal vaccines showing progress.
Area of Science:
- Immunology
- Vaccine Development
- Pharmaceutical Sciences
Background:
- Liposomes and ISCOMs (Immunostimulating Complexes) are established antigen delivery systems.
- Liposomes offer variable physical properties for tailored antigen and adjuvant incorporation.
- ISCOMs contain Quillaja saponin as an inherent adjuvant.
Purpose of the Study:
- To provide an overview of recent developments in liposome and ISCOM technology for antigen delivery.
- To emphasize pharmaceutical aspects and advancements in vehicle design.
- To highlight progress towards clinical applications.
Main Methods:
- Review of recent scientific literature and clinical trial data.
- Analysis of pharmaceutical properties and manufacturing considerations for liposomes and ISCOMs.
- Focus on advancements in saponin-based adjuvants.
Main Results:
- Liposomes allow flexible design for targeting and co-delivery of antigens and adjuvants.
- Progress in defining saponin components for ISCOMs has been significant.
- Clinical trials for ISCOMs are ongoing, and liposomal vaccines are commercially available.
Conclusions:
- Liposomes and ISCOMs continue to be promising platforms for vaccine development.
- Optimized pharmaceutical design and well-defined components are crucial for efficacy.
- The field shows strong translational progress towards approved vaccines.